8.40 0.00 (0.00%)
After hours: 4:39PM EDT
|Bid||8.40 x 1100|
|Ask||8.41 x 900|
|Day's Range||8.35 - 9.05|
|52 Week Range||8.28 - 36.65|
|Beta (3Y Monthly)||2.91|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 5, 2019 - Aug 9, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||17.69|
Shares of drug makers were getting a nice boost in premarket trading Tuesday, after AbbVie Inc.'s deal to buy Allergan PLC for a 45% premium. The SPDR S&P Pharmaceuticals ETF rallied 2.2% ahead of the open. Besides the 31% jump in Allergan's stock, among other shares seeing nice gains in the premarket, Mylan N.V. rose 2.7%, Endo International PLC climbed 4.5%, Theravance Biopharma Inc. hiked up 4.2%, Mallinckrodt PLC tacked on 2.7% and Perrigo Co. PLC gained 2.2%. Meanwhile, Medicines Co.'s stock shed 4.6%, after the company announced late Monday the public offering of $150 million worth of common stock. The pharmaceuticals ETF has lost 7.7% over the past three months through Monday, while the S&P 500 has gained 5.3%.
STAINES-UPON-THAMES, United Kingdom, June 24, 2019 /PRNewswire/ -- Mallinckrodt plc (MNK), a leading global specialty biopharmaceutical company, today confirmed it has achieved 50 percent patient enrollment in the company's Phase 2B study designed to assess the efficacy and safety of Acthar® Gel (repository corticotropin injection) as an investigational treatment for amyotrophic lateral sclerosis (ALS). The U.S. Food and Drug Administration (FDA) previously granted the company's request for a Fast Track designation and orphan status for its Acthar Gel Investigational New Drug application in patients with ALS. Please see Important Safety Information for Acthar Gel below.
The federal government has secured almost $850 million in settlements from the pharmaceutical industry since a Barron’s investigation revealed how companies used charities in ways that undermined efforts to hold back skyrocketing drug prices.
-- Study met primary outcome measure; 63 percent of patients with persistently active RA achieved low disease activity (LDA) as assessed by DAS28-ESR ¹ at Week 12 -- -- Randomized, placebo-controlled, ...
STAINES-UPON-THAMES, United Kingdom , June 11, 2019 /PRNewswire/ -- Mallinckrodt Pharmaceuticals (NYSE: MNK), a global biopharmaceutical company, will present on Tuesday, June 25, 2019 , at the BMO Capital ...
Mallinckrodt Plc NYSE:MNKView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is high * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is extremely high for MNK with more than 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting MNK. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding MNK totaled $9.22 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Mallinckrodt (MNK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Justice Department accused Questcor in the years 2010-2014 of using a patient charity as a means of improperly subsidizing Medicare copayments in order to continue raising prices of H.P. Acthar gel, according to Reuters.
Shares of Mallinckrodt PLC dropped 2.4% in afternoon trade Wednesday, after the biopharmaceutical company said it reached an agreement in principle with the U.D. Department of Justice to resolve the investigation into the legacy sales and marketing activities of Questcor, which Mallinckrodt acquired in August 2014. Mallinckrodt expects to pay $15.4 million in the settlement, which will not contain any admission of wrongdoing. Meanwhile, the company intends to "vigorously defend" itself against any wrongdoing, with respect to the DOJ's newly filed allegations that Questcor's charitable activities between 2010 and 2014 violated the False Claims Act and the Anti-Kickback Statute. The stock has tumbled 58% over the past three months, while the S&P 500 has gained 1.1%.
STAINES-UPON-THAMES, United Kingdom, June 5, 2019 /PRNewswire/ -- Mallinckrodt plc (MNK), a global specialty biopharmaceutical company, today reported the company has reached an agreement in principle with the U.S. Department of Justice (DOJ) to resolve the previously disclosed government investigation of Questcor's legacy sales and marketing activities, which is still subject to the finalization of certain terms. Under the civil False Claims Act settlement, Mallinckrodt expects to pay $15.4 million relating to legacy Questcor activities.
BERWYN, Pa. , May 31, 2019 /PRNewswire/ -- RM LAW, P.C. announces that a class action lawsuit has been filed on behalf of all persons or entities that purchased Mallinckrodt plc (" Mallinckrodt ...
PiperJaffray analyst David Amsellem downgraded the company from Overweight to Neutral, writing that developments last week had blown his bull thesis “to smithereens.”
STAINES-UPON-THAMES, United Kingdom , May 31, 2019 /PRNewswire/ -- Mallinckrodt Pharmaceuticals (NYSE: MNK), a global biopharmaceutical company, will present on Wednesday, June 19, 2019 , at the Raymond ...
Cara (CARA) reports positive top-line data from phase III study of Korsuva injection in hemodialysis patients with moderate-to-severe chronic kidney disease-related pruritus.
STAINES-UPON-THAMES, United Kingdom, May 29, 2019 /PRNewswire/ -- Mallinckrodt plc (MNK), a global specialty biopharmaceutical company, is reporting data1 from the open-label part of the Phase 4, multicenter study assessing the efficacy and safety of Acthar® Gel (repository corticotropin injection) in patients with persistently active rheumatoid arthritis (RA) who were previously treated with disease-modifying anti-rheumatic drugs (DMARDs) and corticosteroids. The data will be reported in a poster presentation on Thursday, June 13 at the European Congress of Rheumatology 2019 (EULAR), June 12-15 in Madrid.
The company had said in December it was open to a sale of the generics business or would spin it off in the second half of 2019. It had said Amitiza would be part of the spun-off unit. Shares of Mallinckrodt were down 6.3% in noon trading, as concerns related to its Acthar gel continued to weigh on the stock.
The stock was rising 5.49% in premarket trading, only to fall 1.77% to $9.44 in regular hours. Mallinckrodt will focus on specialty branded pharmaceuticals while Sonorant will focus on specialty generic products and APIs1 manufacturing. "I am very pleased with the highly experienced management team we have assembled," said Matthew Harbaugh, president of Mallinckrodt's specialty generics business.
Mallinckrodt Plc said on Tuesday it would spin-off its specialty generics unit and rename the remaining specialty branded drugs business to Sonorant Therapeutics Plc. Sonorant will keep constipation medicine Amitiza, Mallinckrodt said. The company had said in December it was open to a sale of the generics business or would spin it off in second half of 2019.
STAINES-UPON-THAMES, United Kingdom, May 28, 2019 /PRNewswire/ -- Mallinckrodt plc (MNK), a global biopharmaceutical company, today announced updated plans for its spin-off of a new company consisting of Mallinckrodt's Specialty Generics/Active Pharmaceutical Ingredients (Specialty Generics) business to Mallinckrodt plc shareholders. The separation is intended to create two independent, appropriately capitalized, publicly traded companies – one focused on innovative specialty branded pharmaceuticals, the other concentrated primarily in specialty generic products and APIs1 manufacturing – with each positioned to optimize future success as they pursue independent growth strategies.